Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
Sumitomo Dainippon Pharma will abandon all of its ongoing PI and PII clinical studies of its investigational anticancer agent napabucasin after a flop in a closely watched global PIII study for colorectal cancer. The Osaka drug maker announced the termination…
To read the full story
Related Article
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
February 10, 2021
- Sumitomo Dainippon’s Napabucasin Flops in Pancreatic Cancer Trial
July 3, 2019
BUSINESS
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
- Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
- Sandoz to Sell, Distribute G-Lasta Biosimilar in Japan
August 26, 2026
- Astellas Starts Global PIII of ASP2138 in Gastric Cancer
August 26, 2026
- Chugai Files Vamikibart in Japan for Uveitic Macular Edema
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…